Health Systems

In HRV terms, health is binding on South African growth because the social returns to labour are being appropriated not by workers and firms but by disease, premature mortality, and a two-tier financing structure that misallocates the country's unusually high health spend. South Africa devotes roughly 8.5% of GDP to health — comparable to some OECD members — yet life expectancy hovers near 65 and the quadruple burden of HIV/TB, non-communicable diseases, maternal-child mortality, and injury suppresses effective labour supply, raises absenteeism, and thins the human capital stock that any diversification strategy presupposes. The split in which roughly half of health expenditure serves the 16% on medical schemes, documented by the Competition Commission's Health Market Inquiry, means the private system is cost-inflated while the public system is capacity-starved: a classic case where the shadow price of the constraint shows up in both fiscal strain and foregone productivity, not merely in queues.

The database's ideas cluster around fixing the financing architecture, the delivery platform, and specific disease burdens in roughly that order of structural depth. The most ambitious is NHI Phased Implementation: Credible Roadmap and Costed Financing Plan, which would only be coherent if paired with the supply-side work in Primary Healthcare Platform Strengthening and CHW Integration — community health workers being the cheapest marginal unit of care delivery and the plausible backbone of any universal scheme. Running alongside these structural reforms, TB Elimination National Acceleration Programme offers the clearest quick-win on labour productivity, given that TB remains a leading cause of death among working-age South Africans. The Health Market Inquiry implementation and tobacco and mental health measures round out the set as regulatory and preventative complements rather than substitutes.

Watch three signals over the next year: whether Treasury and the National Department of Health publish a jointly-costed NHI transition path (as opposed to further framework legislation), whether CHW formalisation moves from policy to accredited posts on the PERSAL payroll, and whether TB case-finding and treatment-completion rates resume their pre-COVID trajectory. Movement on the first two would indicate the constraint is genuinely loosening; movement only on the third means it is being managed, not relieved.